A2Z SMART TECHNOLOGIES ($AZ) Releases Q2 2026 Earnings

A2Z Smart Technologies ($AZ) reported Q2 2026 results on Aug. 12. The company posted EPS of -$0.16, above the -$0.25 estimate, and revenue of $5.9 million, above the $5.24 million estimate. The article also cites institutional investors adding and reducing $AZ positions in recent quarters.

Original reporting
Published Aug 12, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 12:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
A2Z SMART TECHNOLOGIES ($AZ) Releases Q2 2026 Earnings — source image
Decision brief

The 30-second read

$AZBullishMed
01

Why it matters

The only actionable information is the reported beat versus analyst estimates for EPS and revenue; there is no mention of guidance, restructuring, or other new catalysts.

02

Market read

This is a company-specific earnings release with a modest positive surprise versus consensus, which can drive short-term trading around the print.

03

What to watch

Traders may need follow-up data not included here, such as guidance, backlog, gross margin, and cash burn, to judge whether the beat is sustainable.

Relevance 6/10Novelty 6/10Timing: reported Q2 2026 results on Aug 12, after the close or during the session

Background

The piece is a quantitative-style earnings recap for A2Z Smart Technologies’ Q2 2026 results.

Company-level read

Ticker impact

$AZBullishMedium confidence
Context

A2Z Smart Technologies reported Q2 2026 EPS of -$0.16, beating -$0.25 estimates, and revenue of $5.9M above $5.24M estimates.

Expected impact

Likely modest positive reaction versus consensus on the day, but magnitude is uncertain without guidance, cash flow, or forward outlook.

Evidence & confidence

The article provides a clear beat versus estimates (EPS and revenue) but no forward guidance, balance-sheet/cash-flow changes, or segment/margin drivers that would materially reset valuation.

Market effects

Limited spillover because the article lacks sector-wide signals beyond a single microcap earnings print.

No regional macro or cross-border demand signals are provided.

No global supply chain, regulation, or geopolitical linkages are mentioned.

Counterpoint

A headline EPS beat may still reflect weak underlying profitability if costs remain elevated, and the article provides no margin or cash-flow context.

Key entities

  • A2Z Smart Technologies

    Reported Q2 2026 EPS of -$0.16 (vs -$0.25 est.) and revenue of $5.9M (vs $5.24M est.).

Related articles

$AZMed

A2Z CUST2MATE SOLUTIONS CORP. (AZ): Financial results for FY2025

A2Z CUST2MATE SOLUTIONS CORP. (AZ) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 A2Z Cust2Mate Completes Acquisition of In-Store Retail Media Business Hedia ● Strategic acquisition adds an established retail media business with approximately $20 million in annual revenues, advertiser relationships and campaign execution capabilities to Cust2Mate

$AZMedAI 8/10

A2Z Reports Second Quarter 2026 Revenue of $5.9 Million

A2Z Cust2Mate Solutions Corp. (NASDAQ: AZ) reported Q2 2026 revenue of $5.9 million, up from $1.2 million, with Smart Cart revenue of $4.41 million. Gross profit rose to $2.5 million and gross margin to 42.6%. Net loss was $7.3 million. The company cited a $30 million credit line with Bank Leumi and expects $25 million in H2 smart cart revenue.

$AZMedAI 8/10

Allianz enters deal to acquire UOB asset management arm

Allianz Global Investors agreed to acquire UOB Asset Management for S$555m (US$432.7m), covering UOBAM operations in eight Asian markets. UOB and AGI will also form a distribution partnership. UOB expects a pre-tax gain of about S$330m and a CET ratio lift of 14 bps, subject to regulatory approval, with closing in 2027.

$AZMedAI 8/10

Pathos AI signs two cancer deals with Alphamab and AZ

Pathos AI said it licensed Alphamab’s bispecific ADC JSKN016 for solid tumors outside Greater China in a deal worth up to $2.2 billion, including $125 million upfront, up to $2.09 billion in milestones and royalties. JSKN016 targets TROP2 and HER3 and is in Phase 3 for TNBC. Pathos also partnered with AstraZeneca on AZD4241, an ER-targeting PROTAC in preclinical testing for HR-positive, HER2-negative breast cancer.